NICE technology appraisals published

The National Institute for Health and Clinical Excellence (NICE) has issued three new technology appraisals.

Hyposensitisation therapy using low-dose allergens can treat IgE-mediated allergy to bee and wasp venom | SCIENCE PHOTO LIBRARY
Hyposensitisation therapy using low-dose allergens can treat IgE-mediated allergy to bee and wasp venom | SCIENCE PHOTO LIBRARY

Bee and wasp venom hyposentisation agents

NICE has approved Pharmalgen (bee and wasp venom extracts) for use on the NHS to treat bee and wasp venom allergy in patients who have had:

  • a previous severe systemic reaction or
  • a moderate systemic reaction plus one of the following: raised baseline serum tryptase; a high risk of future stings; or anxiety about future stings

View Pharmalgen NICE guidance

Prolonged-release exenatide

Prolonged-release exenatide (Bydureon) is recommended as part of both dual and triple therapy regimens for type II diabetes when adequate glycaemic control is not achieved from other oral hypoglycaemic agents. It is recommended as dual therapy in combination with metformin or a sulfonylurea, or as triple therapy in combination with metformin plus a sulfonylurea or a glitazone.

Dual therapy should only be continued if there is a beneficial metabolic response, defined as a ≥1% point reduction in HbA1C at 6 months. Triple therapy should only be continued if a ≥1% point reduction in HbA1C is observed and the patient has reduced their initial body weight by at least 3% at 6 months.

View Bydureon NICE guidance

Tocilizumab for rheumatoid arthritis

NICE has clarified the recommendations for the use of tocilizumab (RoActemra) in rheumatoid arthritis. The anti-IL-6 receptor antibody can be used in cases that have responded inadequately to DMARDs, another TNF inhibitor and/or rituximab, only if the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.

View RoActemra NICE guidance

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more